Stryker Corporation Q3 2025 Earnings Recap

Stryker reported a strong third quarter with 9.5% organic sales growth and 11.1% adjusted EPS growth, driven by broad demand across its business segments despite tariff pressures.

Key Takeaways

• U.S. organic sales grew by 10.6%, led by double-digit increases in Vascular, Trauma, and Neuro Cranial categories.
• Two strategic acquisitions were completed, enhancing product offerings in wound treatment and patient care.
• Mako robot installations hit a record high, reinforcing Stryker's leadership in the orthopedic market.
• The company increased its full-year outlook, anticipating continued momentum in sales and operating margin improvement.
• The integration of Inari is progressing well, contributing to robust pro forma growth.